Difference in mortality with surgery versus angioplasty in diabetic multivessel patients

Original title: Comparison of coronary artery bypass surgery and percutaneous coronary intervention in patients with diabetes: A meta-analysis of randomized controlled trials. Reference: Verma S. et al. Lancet Diabetes Endocrinol. 2013;Epub ahead of print.

The FREEDOM study was the last of the randomized studies that compared the results of surgery versus coronary angioplasty in diabetic multivessel patients showing a reduction in the relative risk of death, heart attack and stroke by 30% in favor of surgery. While the results of this work were clear, previous studies still left some room for doubt, especially for hard endpoints such as death. 

This study is a meta-analysis of 8 randomized controlled trials in diabetic multivessel patients to surgery or angioplasty. Of all the studies analyzed, 4 used stents (ERACI II, ARTS, SoS and MASS II) and the other 4 used, drug-eluting stents (FREEDOM, SYNTAX, and VA CARDS CARDia). 

At 5 years follow-up  a lower mortality rate was observed with surgery (RR 0.67, CI 0.52 to 0.86, P = 0.002) that was not evident at one year (RR 0.99, CI 0.72 to 1.37, P = .97). The difference in mortality in favor of surgery was similar regardless of the type of stent used (BMS or DES). The rate of nonfatal myocardial infarction was similar both after a year as after five years between the two strategies (RR 1.01, P = 0.98 and RR 0.76, p = 0.3 respectively). The surgery was associated with an increased risk of stroke especially in following year (RR 2.4, P = 0.01 at one year and RR 1.72, P = 0.005 at 5 years). As expected, the greatest difference is given by the rate of revascularization that benefits surgery significantly from the start of monitoring (RR 0.36, p <0.0001 and RR 0.41, P <0.0001, respectively). According to this meta-analysis, the mortality difference disappears when comparing surgery and angioplasty in patients without diabetes (RR 1.03, CI 0.77 to 1.37, P = .78). 

Conclusion: 

Surgical revascularization of diabetic multivessel patients decreases long-term mortality by about one third compared with angioplasty beyond the type of stent used. 

Editorial Comment: 

Unfortunately it is not possible to analyze the anatomical complexity as the SYNTAX score was introduced after the publication of several of the studies analyzed. These findings do not necessarily have to lead to surgery for all diabetics since the presence of 3 vessels is quite heterogeneous. The team discussion of each particular case and the opinion of the patient are essential. 

SOLACI.ORG

More articles by this author

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...

ACC 2025 | FLAVOUR II: Angiography-Derived FFR-Guided vs. IVUS-Guided PCI

Physiological assessment is effective when it comes to decision-making for percutaneous coronary intervention (PCI). However, despite the available evidence, its use remains limited. AngioFFR...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...